top of page

Iambic Therapeutics' Co-Founder and CEO on this month's $50M Series B Extension and the company's AI driven pipeline

Tom Miller describes the rationale for the raise and what it will allow Iambic to do, how he believes the company's AI approach is unique, the lead Her-2 program, and what's behind it.



Comments


Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

NYSE_logo_large_no reg_378x197 (1).png

The NYSE is the world’s largest stock exchange, offering icons and entrepreneurs the opportunity to raise capital and change the world. Our listed companies form a powerful community committed to good governance and societal impact. Industry-leading trading technology, combined with the guidance of experienced traders creates higher market quality for NYSE-market participants

bottom of page